|Day's Range||78.69 - 80.88|
|52 Week Range||31.38 - 86.92|
|PE Ratio (TTM)||-16.55|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Big news is on the way soon for AcelRx, Alnylam, Amgen, Dynavax, and Merck.
Alnylam Pharmaceuticals (ALNY:Nasdaq) By Credit Suisse ($85.21, June 26, 2017) We are raising our target price on Alnylam Pharmaceuticals to $96 from $90 as we increased our probability of success from 40% to 60% in porphyria. At 100% success this adds $12 a share to our model (due to high operating leverage and modeling of fixed costs for the research platform). At 0% success to porphyria our discounted-cash-flow model is $18 a share lower at $78 a share.
How Alnylam, Puma, Immunogen, Sangamo, and Calithera beat all others to be the best biotech stocks of the year so far.